Recap: Freeport-McMoRan Q2 Earnings

  Freeport-McMoRan (NYSE:FCX) reported its Q2 earnings results on Thursday, July 21, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

 

Freeport-McMoRan (NYSE:FCX) reported its Q2 earnings results on Thursday, July 21, 2022 at 08:00 AM.

Here’s what investors need to know about the announcement.

Earnings

Freeport-McMoRan missed estimated earnings by 27.5%, reporting an EPS of $0.58 versus an estimate of $0.8.

Revenue was down $332.00 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.13 which was followed by a 6.76% drop in the share price the next day.

Here’s a look at Freeport-McMoRan’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 0.94 0.92 0.81 0.75
EPS Actual 1.07 0.96 0.89 0.77
Revenue Estimate 6.41B 6.47B 6.18B 5.81B
Revenue Actual 6.60B 6.16B 6.08B 5.75B

To track all earnings releases for Freeport-McMoRan visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Acadia Pharmaceuticals Announces Label Update for NUPLAZID; U.S. FDA Revises Boxed Warning To Clarify That Nuplazid Can Be Used To Treat Patients With Parkinson’s Disease-Related Hallucinations And Delusions Who Also Have Dementia

— U.S. FDA revises Boxed Warning to clarify that NUPLAZID can be used to treat patients with Parkinson's disease-related hallucinations and delusions who also have dementiaSAN DIEGO — September 18, 2023 – Acadia

ACAD